Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut
Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut
Semnur Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company (NASDAQ:SCLX), and Denali Capital Acquisition Corp. (NASDAQ:DECA), a special purpose acquisition company, signed a letter of intent for a proposed business combination.
Scilex Holding Company (纳斯达克:SCLX)全资子公司Semnur Pharmaceuticals Inc.和Denali Capital Acquisition Corp. (纳斯达克:DECA)，一家特殊目的收购公司，签署了股权谅解备忘录，计划进行业务合并。
The deal provides for a pre-transaction equity value of Semnur up to $2 billion, with expected gross proceeds of up to $40 million depending on the number of SPAC shares redeemed before the business combination is completed.
本次交易将为Semnur提供达20亿美元的交易前股权价值，预计募集可达4000万美元的净收益，具体额度取决于交易完成前的SPAC（特殊目的收购公司）股份赎回数量。
Semnur is a clinical late-stage specialty pharmaceutical company focused on developing and commercializing novel non-opioid pain therapies. Semnur's lead program, SP-102 (SEMDEXA), is the first non-opioid novel injectable corticosteroid gel formulation for moderate to severe chronic radicular pain/sciatica, containing no preservatives, surfactants, solvents, or particulates.
Semnur是一家专注于开发和商业化新型非阿片类疼痛治疗药物的临床后期专业药物公司。其主要项目SP-102（SEMDEXA）是一种针对中重度慢性根性疼痛/坐骨神经痛的首个非阿片类新型可注射的皮质激素凝胶制剂，不含防腐剂、表面活性剂、溶剂或微粒。
If approved by the FDA, SP-102 (SEMDEXA) will be available in a pre-filled syringe formulation. It will be administered as an epidural injection for sciatica treatment.
如果获得FDA批准，SP-102（SEMDEXA）将以预充注射器的形式提供，并作为腰麻神经根治疗的一种注射剂治疗坐骨神经痛。
SP-102 completed a Phase 3 trial, meeting primary and key secondary endpoints. The treatment decreased pain intensity for over a month in sciatica patients. It resulted in statistically significant and clinically meaningful improvement in the disability index score while maintaining safety comparable to placebo.
SP-102完成了III期试验，并达到了主要和关键次要终点。该疗法可以在坐骨神经痛患者中减轻一周以上的疼痛强度，并在维持与安慰剂相当的安全性的同时，导致了在残疾指数得分上具有统计学上显著和临床意义的改善。
Sciatica happens when irritation, inflammation, pinching, or compression affects one or more nerves that run down your lower back and into the legs.
坐骨神经痛是一种神经受到刺激、炎症、挤压或压迫而影响下背部并延伸至腿部的疾病。
The parties anticipate seeking approval from the SPAC's shareholders in the second half of 2024.
双方预计将在2024年下半年寻求SPAC股东的批准。
Per Syneos Health Consulting, peak sales potential is projected to be up to $3.6 billion annually five years post-launch.
据Syneos Health Consulting称，五年后，该产品达到峰值销售潜力高达每年36亿美元。
In the U.S., more than 30 million people live with low back and radicular pain.
在美国，有超过3000万人患有腰部和根性疼痛。
According to a proprietary study by Syneos Health, the overall estimated number of epidural steroid injection (ESI) procedures in the U.S. is approximately 12.1 million across all Medicare and private coverage patients, with lumbar radiculopathy/sciatica procedures comprising approximately 88% of all ESIs administered.
依据Syneos Health的专有研究，美国用于硬膜外阻滞类固醇注射（ESI）的总估计手术数量约为1210万例，涵盖所有医疗保险和私人保险的患者，其中腰椎神经根或坐骨神经痛的手术占所有ESI的88%。
Price Action: SCLX shares are up 5.18% at $2.02 at last check Wednesday.
截至上周三最后一次查询，SCLX的股价上涨5.18%，至每股2.02美元。
- Marjorie Taylor Greene Buys Cybersecurity Stock Owned By Nancy Pelosi: Why Trade Could Draw Red Flags
- Marjorie Taylor Greene购买了南希·佩洛西拥有的网络安全概念股票:为什么这笔交易可能引起关注